Glenmark Gets DCGI Nod For Clinical Trials Of Potential Covid-19 Drug
Glenmark Pharmaceuticals has become the first company in India to receive approval from Drug Controller General of India (DCGI) to conduct clinical trials of Favipiravir antiviral tablets for the treatment of Covid-19 patients.
Having internally developed the active pharmaceutical ingredients (API) and the formulations for the product, the company filed the product for clinical trials with the DCGI and has received approval for conducting the trial on mild to moderate patients on Wednesday, Glenmark Pharmaceuticals said in a statement.
The Mumbai-based company is the first pharmaceutical company in India to be given approval by the regulator to start the trial on Covid-19 patients in the country, it added.
Favipiravir has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections, it added. The drug is a generic version of Japan-based Fujifilm Toyama Chemical Co Ltd's Avigan tablets.
ALSO READ: Coronavirus LIVE updates: 830,201 samples tested; India cases at 33,069
As per the clinical trial protocol approved, 150 subjects with mild to moderate Covid-19 will be randomised in the study in a 1:1 ratio to Favipiravir with standard supportive care or standalone standard supportive care, the company said.
Treatment duration is a maximum of 14 days and the total study duration will be a maximum for 28 days from randomisation, it added.
In the past few months, following the outbreak of Covid-19, multiple clinical trials have been initiated on such patients in China, Japan and in the US.
ALSO READ: India needs Rs 65,000 cr to save the poorest and their livelihoods: Rajan
Glenmark Pharmaceuticals Executive Vice President, Global R&D, Sushrut Kulkarni said the company is all geared up to immediately begin clinical trials on Favipiravir on Covid-19 patients in India.
"The clinical trial will let us know the efficacy of this molecule on Covid-19 patients. If the clinical trials are successful, Favipiravir could become a potential treatment for Covid-19 patients," he added.
Shares of Glenmark Pharmaceuticals Ltd rose almost 9% on Thursday after they got an approval to conduct clinical trials with Favipiravir, seen as a potential treatment for Covid-19
HSBC Swings The Axe At UK Wealth In An AI Push
HSBC is preparing deep job cuts across its UK wealth management arm. It plans to cut about half of its management and sp... Read more
Kraken's Owner Buys A Bank: The Lines Are Blurring
Payward, the parent company of the crypto exchange Kraken, has agreed to buy a European bank. It would be the first digi... Read more
Revoluts Australian Banking Licence Game Changer
Revolut has spent much of its life insisting that it is more than a bank. In Australia, it has now decided that becoming... Read more
The AI Bank Is Coming, But Who Controls The Risk?
Artificial intelligence is no longer something banks discuss as a distant possibility. It is already working behind the ... Read more
ClearBank UK Profit Leads To European Growth
ClearBank has spent much of the past decade building the technology and regulatory infrastructure needed to challenge so... Read more